Developing next-generation macromolecule therapeutics

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.
The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity.
This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Science

The Challenge: Endolysosomal trapping of macromolecules

One of the greatest challenges for efficacy of macromolecule therapeutics that act on an intracellular level, is delivery into key cells. Macromolecule therapeutics nowadays rely on receptor-mediated endocytosis into the endosomal compartment. The endo-lysosomal membranes, however, prohibit efficient cytoplasmic access of such foreign substances. The therapeutic efficacy of such drugs is therefore highly dependent on endo-lysosomal vesicles degradation.
Cytosolic delivery of macromolecule therapeutics requires incredibly challenging technical optimizations or specialized drug delivery platforms. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem and exposes a significant need for the development of novel delivery mechanisms.

Our Approach: ENDOSCAPE®

At Sapreme, we are developing improved macromolecule delivery mechanisms by circumventing endosomal entrapment. Our ENDOSCAPE® platform is based on compounds which can release trapped cargo from the endo-lysosomal membranes, improving the therapeutic window and enabling access to intracellular targets with minimal toxicity.
By binding our technology to antibody-conjugated toxins and oligonucleotides, our goal is to enhance target engagement and improve therapeutic efficacy without limitation to biologic modality or indication.

News & Events

Press Releases:

October 7, 2021

Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the round follows promising 2020 and 2021 preclinical data demonstrating the effectiveness of Sapreme’s endosomal escape compound, SPT001. Read the full release here.

Older News

Archive Press Releases

 

Events:

Upcoming events:
8 – 9 March, 2023 | Boston, MA – Targeted Intracellular Delivery Summit

We will be delivering a talk at the first Targeted Intracellular Delivery Summit, in which Sapreme’s highly differentiated tissue specific targeted, intracellular delivery technology will be highlighted.  The Targeted Intracellular Delivery Summit is a new and unique industry touchpoint for optimising the therapeutic index of complex-payload pipelines through novel targeted delivery systems & overcoming critical endosomal biological barriers.  We look forward to sharing our insights and meeting up with the many other trailblazers, current and potential future partners in Boston in March.

Past events:
9 – 11 January, 2023 | San Francisco- JP Morgan Week | Bio 2023

Guy Hermans (CEO) will be returning to San Francisco to represent Sapreme during JPM week. He is looking forward to discuss our recent achievements and is  welcoming opportunities to meet current and future partners to explain our delivery technology and explore how we might collaborate together. Meeting requests are best send through the Bio Partnering system, or send a message to info@sapreme-technologies.com.

13 – 15 June, 2022 | Boston, MA – 2nd Annual Oligonucleotides for CNS Summit

Miriam Bujny  (CDO) will be making an appearance at the 2nd Annual Oligonucleotides for CNS summit in Boston June 13-15. She will be delivering a talk on Efficient on-target delivery of oligonucleotides, showcasing in vitro and in vivo performance of Sapreme’s endosomal escape enhancers for various tissues and targets.

13 – 16 June, 2022 | San Diego, CA – BIO International Convention 2022

In the week of 13 – 16 June, Sapreme will be represented at BIO 2022 in San Diego by Guy Hermans (CEO) and Henrik Luessen (Chief Business Officer). They are primed and ready to meet our current and future partners, explain our targeted, intracellular delivery technology and talk about how we might collaborate together towards truly innovative therapeutics. Do reach out should you find yourself here,  Guy Hermans and Henrik Luessen would be delighted to catch up.

13 – 16 June, 2022 | San Diego, CA – BIO International Convention 2022

In the week of 13 – 16 June, Sapreme will be represented at BIO 2022 in San Diego by Guy Hermans (CEO) and Henrik Luessen (Chief Business Officer). They are primed and ready to meet our current and future partners, explain our targeted, intracellular delivery technology and talk about how we might collaborate together towards truly innovative therapeutics. Do reach out should you find yourself here,  Guy Hermans and Henrik Luessen would be delighted to catch up.

20 & 21 April, 2022 | Boston, MA – 3rd Annual RNAi-based Therapeutics Summit

Guy Hermans (CEO) will be attending, and speaking at the 3rd Annual RNAi-Based Therapeutics Summit.  His presentation on “Efficient on-target delivery of oligonucleotides to the liver and beyond: in vitro performance of Sapreme’s endosomal escape enhancers” at the start of the first day is one not to miss!

25 – 27 April, 2022 | Boston, MA   – Novel Format Conjugates Summit

Ruben Postel, founder and CSO, will be speaking in person on Tuesday 26th April at the Novel Format Conjugates Summit in Boston, MA. In his talk, he will discuss improved receptor-targeted cytoplasmic delivery of macromolecule payloads using Sapreme’s endosomal escape enhancers.

About Sapreme:

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contacts: Guy Hermans, CEO +31 30 760 09 76 hermans@sapreme-technologies.com

For Media Inquiries, please contact: Trophic Communications Eva Mulder or Valeria Fisher +49 89 238 877 30 sapreme@trophic.eu

Careers

Sapreme Technologies is a privately-owned biotech company developing a disruptive technology platform (ENDOSCAPE®) enabling the development of superior targeted therapeutics, such as antibody-drug conjugates and oligonucleotide-based drugs. We have seen rapid growth this year, and continue to recruit on a frequent basis. Please see our most recent opportunity listed here:

Bioconjugation Project Leader | new!

Sapreme is projecting further growth in 2023 and we are currently recruiting for a Bioconjucation Project leader to join the team. You will join an ambitious young company full of potential and develop new medicines for cancer and other indications. Projects span both internal pipeline as well as pharma and biotech partnered programs, allowing for external interaction.

In this role, you will serve as subject matter expert (SME) and project lead (CRO liaison) for all bioconjugation activities at Sapreme. These projects are aimed at the development of novel complex (ADC-like) bioconjugates with our proprietary endosomal-escape compounds, linker technologies and scaffolds. You will define bioconjugation strategies and lead work packages across all of Sapreme’s projects and pipeline. To this end, you will work in close partnerships with your colleagues from Chemistry, Biologics and Product Development. Work packages are mainly executed at partners and specialty CROs/CDMOs. For work carried out in our state-of-the-art labs, you would serve as SME for lab-based R&D staff, or perform lab-based work yourself.

To excel in this role, the successful candidate will have a solid background in protein chemistry and biochemistry. You should have extensive experience in the development of targeted therapeutics, including but not limited to antibody conjugates, nucleic acid conjugates, and/or protein-nanomaterial conjugates and scaffold-linker technologies. Your expertise and leadership will critically influence Sapreme’s platform development and pipeline. Your expertise in working with proteins and/or protein conjugates will add value to Sapreme, enabling development of a breakthrough technology for intracellular delivery of targeted therapies.

The full job description is available here.
Hiring manager Miriam Bujny welcomes any questions you may have on the position, or submit your application directly to: careers@sapreme-technologies.com. To be considered for this role, you must include a letter of motivation.

Senior Technician Bioanalysis | * position filled

We are rapidly expanding and herewith announcing the new vacancy for a Senior Technician Bioanalysis.  You will join an ambitious, entrepreneurial team and develop new medicines for cancer and other indications. Projects span both internal pipeline as well as pharma and biotech partnered programs, allowing for external interaction.  In this role, you will be responsible for assay development and sample analysis of Sapreme’s bioconjugates. This includes the characterization of antibody-drug conjugates and other proprietary medicinal scaffolds according to industry-standard quality systems in cell-based in vitro systems (e.g., for dose predictions and assay validation), but also the assay set up and analysis of biospecimens from subsequent in vivo studies. You will work in a matrixed structure, contributing to deliverables in the R&D department and Development pipeline projects.

The full job description is available here.
Hiring manager Miriam Bujny welcomes any questions you may have on the position, or submit your application directly to: careers@sapreme-technologies.com

Senior Research Technician Cell Biology / Lab Manager  |  * position filled

To grow our capacity for internal drug development pipeline and partnered programs, we currently have a vacancy for a Senior Research Technician / Lab manager as part of the Cell Biology Team. You will contribute to the day-to-day activities in the laboratory and (cell biological) experimental work. You will also be responsible for all lab managerial tasks including ordering, ensuring stock maintenance, administering cell- and GMO repositories. Projects span both the internal pipeline as well as pharma- and biotech partnered programs.

You will work closely together with the other Research Technicians and Scientists within Sapreme Technologies. Click here to read the full job spec and apply. We welcome any questions you might have about this opportunity. Please feel free to reach out to the hiring manager Ruben Postel, or submit your application directly to: careers@sapreme-technologies.com. Applications close Sunday Dec 18.

Sapreme Technologies is a privately-owned biotech company developing a disruptive technology platform (ENDOSCAPE®) enabling the development of superior targeted therapeutics, such as antibody-drug conjugates and oligonucleotide-based drugs. We have seen rapid growth this year, and continue to recruit on a frequent basis. Please see our most recent opportunity listed here:

Open applications welcome

If you are a talented individual interested in contributing to our mission, please send your resume to careers@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76

Address

Antonie van Leeuwenhoeklaan 9
USP Bilthoven A12-1
3721 MA Bilthoven
The Netherlands